Emerging IL-12 family cytokines in the fight against fungal infections.

Thompson, A., & Orr, SJ. (2018). Emerging IL-12 family cytokines in the fight against fungal infections. Cytokine. https://doi.org/10.1016/j.cyto.2018.05.019

Published in:
Cytokine

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2018 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Emerging IL-12 family cytokines in the fight against fungal infections

Aiysha Thompson, Selinda J. Orr*

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4XN, Wales, United Kingdom

ARTICLE INFO

Keywords:
Fungal
IL-12
IL-23
IL-27
IL-35

ABSTRACT

Invasive fungal infections cause approximately 1.5 million deaths per year worldwide and are a growing threat to human health. Current anti-fungal therapies are often insufficient, therefore studies into host-pathogen interactions are critical for the development of novel therapies to improve mortality rates. Myeloid cells, such as macrophages and dendritic cells, express pattern recognition receptor (PRRs), which are important for fungal recognition. Engagement of these PRRs by fungal pathogens induces multiple cytokines, which in turn activate T effector responses. Interleukin (IL)-12 family members (IL-12p70, IL-23, IL-27 and IL-35) link innate immunity with the development of adaptive immunity and are also important for regulating T cell responses. IL-12 and IL-23 have established roles during anti-fungal immunity, whereas emerging roles for IL-27 and IL-35 have recently been reported. Here, we discuss the IL-12 family, focusing on IL-27 and IL-35 during anti-fungal immune responses to pathogens such as Candida and Aspergillus.

1. Introduction

Interleukin (IL)-12 family members (IL-12p70, IL-23, IL-27 and IL-35) link innate immunity with the development of adaptive immunity [1]. They are important in regulating T cell responses and while structurally similar, they display different functional activities. IL-12 and IL-23 are both considered to play different inflammatory roles. IL-12 predominantly favors T helper (Th)1 cell differentiation [4-6], whereas IL-23 enhances Th17 responses and is involved in the activation and expansion of memory T-cells [7,8]. IL-27 has both pro- and anti-inflammatory properties and is a potent T cell immunomodulator. IL-27 was originally reported to enhance Th1 cell differentiation [9,10]. However, subsequent studies highlight more nuanced roles linked with suppression of adaptive immunity, where IL-27 inhibits IL-2 signaling, antagonizes Th17 cells and promotes regulatory T cells (Tregs) responses [11-16]. Lastly, IL-35 induces Tregs and regulatory B cells (Bregs) and suppresses T cell responses [17]. IL-12 and IL-23 have established roles during anti-fungal immunity [7,18-29] and new roles for IL-27 and IL-35 have recently been reported [20,23,30]. Importantly, the new roles reported for IL-27 as a regulatory cytokine emerged from infection studies suggesting that IL-27 may also have important roles in fungal control. This review will focus on the role of these newer family members during fungal infections, such as Candida and Aspergillus infections.

Candida species (spp.) cause various types of disease, from mucosal infections (e.g. oral and vaginal thrush) to life threatening invasive candidiasis. Candida spp. bind various Pattern Recognition Receptors (PRRs) such as C-type lectin-like receptors (CLRs) including Dectin-1, Toll-like receptors (TLRs) and Nucleotide-binding Oligomerisation domain-like receptors (NLRs) on myeloid cells [31]. This induces multiple cytokines, which in turn activate Th1 and Th17 responses [32-38]. The production of IFN-γ by Th1 cells has been shown to be crucial in the control of systemic candidiasis in a murine model [21,39-41]. Whereas, the Th17 response protects against oropharyngeal and mucocutaneous models of candidiasis while increasing disease susceptibility in a gastrointestinal model [7,29,42,43].

Aspergillus fumigatus is an airborne fungus that causes various types of disease including invasive pulmonary aspergillosis (IPA) and allergic bronchopulmonary aspergillosis (ABPA). An important role of the host immune response is to limit spore germination and restrict hyphal invasion. Spore swelling, the first step of germination, exposes fungal ligands that bind to CLRs and TLRs resulting in inflammatory cytokine production [44,45]. This then induces a Th1 response and a much smaller Th17 response in a pulmonary infection model [25,46] whereas a Th2 response is induced in an allergic model of disease [47,48].

The T cell responses mediated by these different pathogens (Candida and Aspergillus) are likely controlled by the ligands exposed on their cell surface and by the environment (e.g. systemic, mucosal, pulmonary) of the infection. The yeast form of C. albicans expresses mannans on the cell surface and β-glucans are rapidly exposed at bud scars whereas dormant Aspergillus conidia are covered in a rodlet layer that initially hides β-glucans from the immune system [44,49,50]. Mannans present on the yeast form of C. albicans have been shown to induce IL-1β and IL-23 in a Dectin-2 dependent manner [37]. Additionally, both yeast and

* Corresponding author.
E-mail address: orrs@cardiff.ac.uk (S.J. Orr).

https://doi.org/10.1016/j.cyto.2018.05.019
Received 9 April 2018; Received in revised form 17 May 2018; Accepted 19 May 2018
Available online 21 May 2018

1043-4666/ © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
hyphal forms of \textit{C. albicans} induced Dectin-2-dependent Th17 differentiation in \textit{vitro} and \textit{in vivo} [37]. Further to this, dendritic cells (DCs) activated by Dectin-1 engagement by curdlan, a β-glucan preparation, demonstrated Th17 cell differentiation of CD4+ T cells \textit{in vitro}, and the use of curdlan as an adjuvant \textit{in vivo}, promoted both Th17 and Th1 responses [34]. We have previously demonstrated differences in T cell differentiation \textit{in vitro} and \textit{in vivo}. Heat killed yeast predominantly induced Th17 differentiation \textit{in vitro}, whereas, mice systemically infected with \textit{C. albicans} displayed a Th1-biased response \textit{in vivo} [19], therefore the environment is also important for determining T cell bias. In the context of \textit{A. fumigatus} infections, Th1 and Th17 CD4+ T cells are driven via TLR/MyD88 and Dectin-1 respectively. TLR2 and TLR4 recognise \textit{A. fumigatus} conidia [51], whereas Dectin-1 recognises later morphological forms such as swollen conidia and early germlings [44]. It is possible that the TLRs initiate a Th1 response to \textit{A. fumigatus} and then Dectin-1 induces the Th17 response once germination of \textit{A. fumigatus} is further underway. As \textit{C. albicans} and \textit{A. fumigatus} engage different combinations of PRRs, interactions between these PRRs likely dictate the balance between Th1 and Th17 responses to these two pathogens.

2. IL-12 family cytokines

2.1. Structure

IL-12 family cytokines consist of four heterodimeric proteins (Figs. 1 and 2), which are mainly produced by myeloid cells. This has been extensively reviewed elsewhere [22,52-57]. IL-12 is made up of 2 subunits, IL-12p35 and IL-12p40, which together form active IL-12p70. IL-12p70 is a very potent activator of Th1 cell responses [4,5]. IL-12p40 is also expressed and secreted as a monomer and a homodimer [58,59]. The p40 monomer has no biological function whereas the homodimermer is an antagonist of IL-12p70 by competitively binding the IL-12R [60]. The IL-12p40 homodimer enhances alloantigen-specific Th1 development suggesting similar functional activity to IL-12p70 under certain conditions [61]. IL-23 is composed of IL-23p19 and IL-12p40 (shared with IL-12p70). IL-23 is tightly regulated and is functionally distinct from IL-12. IL-27 is a heterodimer made up of IL-27p28 and Epstein Barr virus induced gene 3 (EBI3) subunits [10,62]. IL-27p28 has also been shown to be expressed as a monomer, which can inhibit IL-6, IL-27 and IL-11 signalling through the common gp130 signalling receptor [63,64]. IL-27 modulates pro- and anti-inflammatory signaling [65-67]. IL-35 consists of the EBI3 subunit (shared with IL-27) and the IL-12p35 subunit (shared with IL-12) [68]. IL-35 promotes Treg responses and suppresses Th1 and Th17 responses. Treg cells deficient in either Ebi3 or Il12a (IL-12p35) display a reduced ability to inhibit effector T cell proliferation [69-72].

2.2. Signaling

IL-12 binds to IL-12Rβ1 and IL-12Rβ2 and signals via Janus associated kinase 2 (JAK2) and tyrosine kinase 2 (Tyk2) to activate various signal transducer and activator of transcription (STAT) family members [3,73] (Fig. 1). Patients with defective IL12B or IL12RB1 [74] and cells from mice deficient for Tyk2 or STAT4 showed reduced IFN-γ production in T cells and natural killer (NK) cells [75-77]. IL-23 binds IL-12Rβ1 and IL-23R [78,79] and signals in a similar manner to IL-12 [79,80] (Fig. 1). JAK2 and Tyk2 constitute a pathway associated with IL-23R and IL-12-12Rβ1 chains respectively [79]. IL-23 activated STAT3 and STAT4 is critical for IL-17 induction from Th17 cells [81,82]. The IL-23R and IL-12-12Rβ1 chains alone lack intrinsic enzymatic activity [2,3,79,83].

IL-27 signals through IL-27Rα (WSX-1/TCCR) paired with glycoprotein (gp)130 [84] (Fig. 1). IL-27 can bind WSX-1 with low affinity in the absence of gp130, however both IL-27R subunits are required for effective signal transduction [10,84]. IL-27 signaling activates various JAK and STAT family members in a cell-specific manner. For example, IL-27 activates both STAT1 and STAT3 in naïve CD4+ T cells but in fully active T cells only STAT3 activation is retained [85]. IL-35 signaling is unconventional as it utilizes different receptor combinations including IL-12Rβ2 and gp130 homodimers and heterodimers (Fig. 2). STAT1 and/or STAT4 are activated depending on which receptor homodimer/heterodimer is engaged. In B cells IL-35 signals through IL-12Rβ2 and WSX-1 to activate STAT1 and STAT4. More work is required to fully understand IL-35 signaling downstream of the different homodimers or heterodimers [17,86].

3. IL-12 family cytokines in anti-fungal host defense

3.1. IL-12

IL-12 is induced by microbial products in monocytes, macrophages and DCs and acts on NK and T cells to induce IFN-γ, IFN-γ in turn activates monocytes and macrophages to induce further IL-12 production [87]. This positive feedback mechanism helps protect against certain pathogens that induce low IL-12 levels [88]. Deficiency of IL-12 or IL-12 genes leads to impaired cell mediated immunity and enhanced disease susceptibility [89-92]. We will only briefly discuss the role of IL-12 during \textit{Candida} infections as this has been reviewed elsewhere [22,93].

Several \textit{C. albicans} infection experiments have been performed in mice deficient in different components of the IL-12 family (Table 1). However, due to subunit sharing between different family members, interpretation of these results is rather complex. Overall, IL-12 appears to be important during systemic infection but less important during mucocutaneous infections. Il12p40−/− mice were susceptible to oral infection with \textit{C. albicans}, however, this was mainly attributed to IL-23 and Th17 responses [29]. Interestingly, Il12p35−/− mice demonstrated disseminated infection following oral infection with \textit{C. albicans} suggesting that while IL-12 is not overly important in the local response during an oral infection, it controls systemic dissemination [29]. In addition, Il12p35−/− and Il12−/− mice displayed enhanced susceptibility to systemic infection with \textit{C. albicans} [7,39-41], indicating an important role for IL-12/Th1 responses during systemic infection. Il12p40−/− mice displayed variable susceptibility to systemic infection in different studies [7,26,94]. Additionally, in a mouse model where mannoproteins from the fungal pathogen \textit{Cryptococcus neoformans} were shown to protect against systemic \textit{C. albicans} infection, this protective response was reversed upon IL-12 blockade [95]. Further, when IL-12 was fused to enolase (a \textit{C. albicans} antigen) and administered during systemic infection with \textit{C. albicans}, mice demonstrated increased survival and decreased fungal burden in their kidneys [27]. However, administration of IL-12 during systemic infection increased disease severity due to IFN-γ mediated pathology [96]. These data suggest that while IL-12 and IFN-γ are important for controlling systemic infections with \textit{C. albicans}, this response needs to be finely tuned for optimal fungal clearance while minimising pathology.

The importance of IL-12 has also been demonstrated during \textit{A. fumigatus} infections. Human DCs infected with \textit{A. fumigatus} induced IL-12p70 production and promoted IFN-γ production from CD4+ T cells [20]. Rivera et al. [25] showed that Th1 and Th17 responses are induced during an \textit{in vivo} model of \textit{A. fumigatus} lung infection. The authors showed that TLR and Dectin-1 pathways modulate the balance between Th1 and Th17 populations by controlling production of IL-12 family members. In addition, IL-12 has been shown to induce human monocytes to damage \textit{A. fumigatus} hyphae via an oxidative burst response in an IFN-γ-independent manner [97].

During an \textit{in vivo} infection model with \textit{A. fumigatus}, Cenci et al. [98] compared the immune response of resistant (intact DBA/2 mice) and susceptible (leukopenic DBA/2 mice) mice. Interestingly, the authors demonstrated that resistant mice produced high levels of IL-12, TNF
and IFN-γ while susceptible mice produced an IL-10 and IL-4 skewed response. In addition, immunosuppressed Il12p40−/− and Ifng−/− mice were more susceptible to invasive pulmonary aspergillosis [99]. In agreement with this, Nagai et al. [100] showed that administration of IFN-γ protected mice from invasive aspergillosis. Furthermore, Delsing et al. [101] showed that adjunctive therapy with IFN-γ and an anti-fungal drug partially restored immune function in patients with invasive Candida and/or Aspergillus infections indicating that further clinical studies are warranted to fully determine the potential clinical benefits of IFN-γ therapy during invasive fungal infections.

3.2. IL-23

IL-23 is involved in the maintenance of Th17 cells and the activation of memory T-cells [78,102]. It induces CD4+ Th17 cells to produce IL-17 and IL-22 [80,103–105]. IL-17A is a proinflammatory cytokine that promotes neutrophil recruitment via upregulation of other cytokines and chemokines [106]. While the IL-23-IL-17 pathway is important for protective responses against infection, it can also contribute to autoimmunity and increased pathology [107,108]. IL-23 is also important for regulation of innate lymphocyte cells (e.g. innate lymphoid, NK, NKT and γδ T-cells [109]).

*C. albicans* induces IL-23p19 and/or IL-23 in cultured macrophages and DCs and at sites of inflammation during infection [19,24]. Interestingly, human monocyte derived DCs produced IL-23 when challenged with *C. albicans* hyphae, whereas *C. albicans* yeast induced IL-12 production and IL-23 was only produced with high concentrations of yeast [110]. This suggests that the hyphal form of *C. albicans* triggers the Th17 response in vivo.

During systemic infection with *C. albicans*, IL-23 was dispensable, however the IL-23/Th17 pathway is important during chronic mucocutaneous candidiasis (CMC) [7]. *Il23p19−/−* and *Il17ra−/−* mice were more susceptible to oral *C. albicans* infection [29]. However, Yano et al. (2012) found that fungal burden and S100A8/S100A9 alarmin-mediated neutrophil recruitment was normal in *Il23p19−/−*, *Il17ra−/−* and *Il22−/−* mice in a mouse vaginal infection model suggesting that the vaginal alarmin S100 response is independent of the IL-23/Th17 axis [111]. In contrast, several other studies have found important roles for Th17 cells, IL-17 and IL-22 in protecting patients against CMC [29,43,112]. Patients with impaired Th17 and Th17-associated cytokines due to mutations in genes such as STAT3 (hyper IgE syndrome, [113,114]), IL-17RA [115], IL-17F [115], ACTI [116], STAT1 [117,118], AIRE [119,120], IRFS [121], CARD9 and DECTIN-1 [122–124] are prone to CMC. In addition, two Mexican patients with a mutation in IL12RB1, suffered from infections with Baccille Calmette-Guérin (BCG) and *C. albicans* and they both died early at ages 4 and 16.
Furthermore, in an international study of 141 patients, 23% of patients lacking IL12RB1 were found to suffer from CMC [126]. However, as both IL-12 and IL-23 signal through IL-12Rβ1, this could be due to a lack of responsiveness to either cytokine. IL-23 and IL-6 were detected in vaginal secretions from women infected with vaginal candidiasis [24,127]. Additionally, healthy PBMCs stimulated with C. albicans induced a Th17 response demonstrating that Th17 cells are involved in the defense against C. albicans [128]. Furthermore, reduced detected in vaginal secretions from women infected with vaginal candidiasis [24,127]. Additionally, healthy PBMCs stimulated with C. albicans induced a Th17 response demonstrating that Th17 cells are involved in the defense against C. albicans [128].

Table 1: Effects of different Candida and Aspergillus infections on Il12p40−/−, Il12p35−/−, Il23p19−/− and Il27ra−/− mice.

| Genotype | Pathogen | Outcome | References |
|----------|----------|---------|------------|
| Il12p40−/− | C. albicans | Susceptible to oral challenge | Farah et al. [26] |
| C. albicans | Reduced fungal burden during systemic challenge (1, 3 days post infection) but increased fungal burden following re-infection | Mencacci et al. [94] |
| C. albicans | No effect during systemic challenge | Netea et al. 2003 [170] |
| C. albicans | No effect during systemic challenge (5 days post infection) | Farah et al. 2006 [26] |
| C. albicans | Increased fungal burden during gastrointestinal challenge (3, 10 days post infection) | Zelante et al. [7] |
| C. albicans | Susceptible to cutaneous challenge | Kagami et al. [112] |
| C. albicans | Increased fungal burden during gastrointestinal challenge | Mencacci et al. [94] |
| A. fumigatus | Increased fungal burden during IPA in immunosuppressed mice | Cenci et al. [99] |
| A. fumigatus | Reduced fungal burden during IPA | Zelante et al. [7] |
| Il12p35−/− | C. albicans | Systemic dissemination during oral challenge | Conti et al. [29] |
| C. albicans | Susceptible to gastrointestinal challenge | Zelante et al. [7] |
| C. albicans | No effect during cutaneous challenge | Kagami et al. [112] |
| A. fumigatus | Reduced fungal burden during IPA | Zelante et al. [7] |
| Il23p19−/− | C. albicans | Susceptible to oral challenge | Conti et al. [29] |
| C. albicans | No effect during gastrointestinal challenge | Zelante et al. [7] |
| C. albicans | No effect during vulvar challenge | Yano et al. [111] |
| C. albicans | Susceptible to cutaneous challenge | Kagami et al. [112] |
| A. fumigatus | Reduced fungal burden during IPA | Zelante et al. [7] |
| Il27ra−/− | C. albicans | No significant effect during systemic challenge | Patin et al. [30] |
| C. parapsilosis | Enhanced fungal clearance and reduced fungal burden in the kidneys during systemic challenge (6 weeks post infection) | Patin et al. [30] |
Th17 responses have been reported in human PBMCs stimulated with C. albicans from patients with hyper IgE syndrome, demonstrating that Th17 cells play an important role in the defense against C. albicans [113]. These data indicate a protective role for the IL-23/Th17 pathway during C. albicans infection, however, heightened IL-17 and IL-23 responses can also negatively regulate Th1 responses to C. albicans resulting in increased inflammation and susceptibility to candidiasis [7]. Therefore, similar to IL-12 and IFN-γ, the IL-23/Th17 response needs to be tightly controlled. Th17 cells express IL-10Rα and IL-10 signalling has been shown to control IL-17A producing CD4+ T cells in a colitis model [129], suggesting that IL-10 may be an important regulator of IL-23/Th17 responses during anti-fungal immunity.

Studies have demonstrated a role for the IL-23/Th17/IL-17 pathway during A. fumigatus infection [7,130]. Il12p40−/−, Il12p35−/− and Il23p19−/− mice displayed reduced fungal burden in the lungs of A. fumigatus infected mice, indicating that a heightened IL-23/Th17 response is associated with susceptibility [7]. However, Dectin-1 and TLR9 deficient mice displayed reduced IL-23, IL-17A and/or IL-22 responses and increased fungal burden in the lungs of A. fumigatus challenged mice, indicating that the IL-17 pathway is involved in a protective response to A. fumigatus [131,132]. In contrast, an immunopathogenic role for Dectin-1 and IL-22 has been shown during chronic fungal allergy [104], once again demonstrating the importance for tight regulation of these pathways. IL-17 has been shown to inhibit neutrophil mediated killing of A. fumigatus and in vivo clearance [7]. Th1 cells, Treg cells, and Th17 cells are all important in producing both an inflammatory and anti-inflammatory response against A. fumigatus [7,48,133]. The balance between Th17 cells and Treg cells has been suggested to be important in determining whether commensal C. albicans causes infection and the same could be true for Aspergillus infections [134,135].

3.3. IL-27

The ability of IL-27 to regulate T cell responses has been reviewed elsewhere [136,137]. Briefly, IL-27 was shown to enhance in vitro Th1 cell differentiation [138]. However, more recently, anti-inflammatory properties of IL-27 have been discovered. IL-27 has been shown to inhibit T cell responses by negatively regulating IL-2 signaling and by inducing IL-10 [11,12,66,139–142]. IL-10 has been shown to inhibit both CD4+ and CD8+ T cell responses [134,134]. Additionally, a role in inhibiting Th17 cell differentiation has been demonstrated to protect against Th17 associated disease, such as encephalomyelitis [11–14]. Th17 cells in encephalomyelitis promotes the development of ectopic lymphoid structures in the central nervous system [144]. Interestingly, IL-27 inhibits the development of ectopic lymphoid structures in inflamed tissues [145]. These functions of IL-27 help protect against T-cell driven pathology. IL-27 has shown contrasting effects on regulatory T cells. It has been shown to promote Treg growth and survival at sites of infection [16] but also to indirectly inhibit Treg development by inhibiting IL-2 production [15,16].

IL-27 has been reported to be involved in the immune response to various pathogens including Trypanosoma cruzi [146], Leishmania major [147–149], Mycobacteria tuberculosis [11] and Toxoplasma gondii [12,14,150]. In addition, a limited number of studies reviewed here, have recently examined the role of IL-27 in response to fungal pathogens. The first report in a fungal model demonstrated that EBIS levels were significantly induced in human monocyte derived DCs following stimulation with A. fumigatus while IL27 levels only showed a slight increase, demonstrating that A. fumigatus-induced IL-27 production is minimal [20]. Indeed, it is possible that the increased EBIS levels could actually reflect IL-35 induction rather than IL-27 production, as human monocyte derived tolerogenic DCs express and produce IL12A and EBIS [151], although this remains to be determined in a fungal model. However, in a later study these authors went on to show that IFN-β treated DCs challenged with A. fumigatus resulted in increased IL27 mRNA levels, IL-12p70 production and increased expression of CD86 and CD83 [152]. While it is well established that IFN-β induces IL-27 [153], this report describes a new role for A. fumigatus in IL-27 production [152]. Further, DCs stimulated with IFN-β and challenged with A. fumigatus resulted in increased Th1-mediated IFN-γ production [152]. This suggests that IFN-β could be used as a possible therapy to enhance a beneficial Th1 response during infection with A. fumigatus.

Type 1 regulatory T cells (Tr1) are instrumental in protecting against Th1/Th17-mediated autoimmunity in mice and reactions to common allergens in humans [154,155], and may also play an important role during A. fumigatus infections [156]. Tr1 cells are Foxp3 regulatory T cells that produce high IL-10 levels and suppress T cell expansion in vitro and in vivo [157]. Bedke et al. [156] identified Crf-1/p41-specific latent associated peptide and IL-10+ Tr1 cells in healthy humans and in mice following vaccination with an Aspergillus peptide (Crf-1/p41) and zymosan. In agreement with previous studies [158,159], Th1 cell differentiation in vivo was found to be dependent on the aryl hydrocarbon receptor, c-Maf and IL-27. These data indicate that IL-27 plays a role in maintaining anti-fungal immune homeostasis via induction of Tr1 cell differentiation [156].

Several inflammatory cytokines/molecules, such as lipopolysaccharide (LPS) [10,22,160,161], IL-1β [162], Poly(I:C) [161] and IFN-β [152,153,163], have been reported to induce IL-27 as a protective response to prevent excess inflammation. Interestingly, increased expression of IL27 and EB13 has been shown to induce IL10- and IL17- and IL-27 production, which then signaled through the IFN-α/β receptor (IFNAR) and STAT1/2 to induce IL-27 (Fig. 3). Interestingly, while we found that C. albicans did not induce IL-27, likely due to the absence of IFN-β induction, it also actively blocked C. albicans-induced IL-27 via a soluble mediator [30]. This soluble mediator has yet to be identified, but it is tempting to speculate that BBG might induce the same soluble mediator to block IL-27 production [160]. However, it is interesting to note that live C. albicans blocked C. parapsilosis-induced IL-27 in mouse BMDMs [30] while heat killed C. albicans enhanced LPS-induced IL-27 in the human THP-1 cell line [22]. These discrepancies could be due to differences in mouse vs human IL-27 cells or due to exposure of different ligands on live vs heat killed C. albicans and requires further study to unravel these differences.

Similar to infections with other pathogens such as M. tuberculosis, P. berghei and T. gondii [11,164], we demonstrated improved clearance of systemic C. parapsilosis infection in WSX-1 (Il27ra) deficient mice. This was accompanied by increased IFN-γ and IL-17 T cell responses in addition to increased serum pro-inflammatory cytokine levels [30]. While we observed improved fungal clearance and only a modest increase in inflammation, other groups have shown improved pathogen clearance in WSX-1 deficient mice accompanied by fatal organ pathogenesis due to highly elevated pro-inflammatory responses [11,12,164]. Interestingly, some studies showed that organ pathology could be prevented by depleting CD4+ T cells but not CD8+ T cells [12,164]. As C. parapsilosis induced a CD8+ T cell biased response rather than a CD4+ T cell response, this could account for the improved fungal clearance without inducing fatal organ pathology [30]. These data suggest that blocking IL-27 during infection with C. parapsilosis could have therapeutic benefits.

In this review, it has already been mentioned that Th17 cells, IL-17, IL-22 and IL-23 cytokines have important role in protecting patients
against CMC [7,24,29,43,112]. Patients with a gain of function mutation in STAT1 have higher susceptibility to Candida infections [165]. Further, increased STAT1 function showed increased IL-27, IFN-γ and IFN-α production but reduced IL-17 responses [165–167]. In a separate study, it has been reported that reduced IFN-γ and IL-27 responses from impaired STAT1-expression was observed in two unrelated patients (from Japan and Saudi Arabia) with heterozygous missense mutations in the STAT1 SH2 domain [168]. Further studies in both mice and humans are required to fully unravel the role of IL-27 during anti-fungal immunity.

3.4. IL-35

IL-35 is mainly produced by Bregs and Tregs [169]. Stimulation of naïve effector T cells with recombinant IL-35 suppressed T cell proliferation in a murine model and ectopic expression of IL-35 on naïve T cells conferred regulatory activity [71]. IL-35 has been shown to suppress immune responses important for the induction of inflammatory disease in murine models such as collagen-induced arthritis [69,71]. However, human T regulatory cells do not express IL-35 and as result a role for IL-35 in humans remains unclear [72]. As cytokine subunits are shared between IL and 35, IL-12 and IL-27, mechanistic studies to determine specific roles for IL-35 in the regulation of anti-fungal immunity are challenging.

Il12p35−/− mice have been shown to have lower fungal burden during oral candidiasis. As IL-12p35 is a subunit of IL-35, it is possible that IL-35 may play an important role in reducing tissue damage during oral infection [29]. Recently, heat killed C. albicans was shown to suppress LPS-induced IL-12p70 production in M2 macrophages due to increased Ebi3 expression, a subunit of IL-35. Further, the authors demonstrated that C. albicans induced IL-35 production, which inhibited an LPS-induced M2 (anti-inflammatory) to M1 (inflammatory) phenotype change in BMDMs, thereby suppressing an inflammatory response. These results demonstrate a possible mechanism for how C. albicans is able to evade immune detection [23].

4. Conclusions

IL-12, IL-23, IL-27 and IL-35 are critical cytokines in innate and adaptive immune responses against fungal infections. They are important in regulating T cell responses and exert their effects on the Th1, Th17 and Treg immune pathways of T cell differentiation. These cytokines are important in regulating the development of inflammation and disease progression. A better understanding of the IL-12 receptor cytokine family, particularly the newer members (IL-27 and IL-35) is invaluable to fully unravel the importance of targeting this family to develop immunotherapies to help fight fungal infections.

Acknowledgements

We would like to thank Gareth Jones and Ian Humphreys for critically reviewing this manuscript.

Funding

SJO is funded by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number 099953/Z/12/Z).

References

[1] X. Ma, G. Trinchieri, Regulation of interleukin-12 production in antigen-presenting cells, Adv. Immunol. 79 (2001) 55–92.
[2] D. Yen, J. Cheung, H. Scheerens, F. Poulet, T. McClanahan, B. McKenzie, M.A. Kleinschek, A. Owyang, J. Mattson, W. Blumenschein, E. Murphy, M. Sathe, D.J. Cua, R.A. Kastelein, D. Rennick, IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6, J. Clin. Invest. 116 (5) (2006)
A. Thompson, S.J. Orr

Cytokine 111 (2018) 398–407

[16] A.O. Hall, D.P. Beiting, C. Tato, B. John, G. Oldenhove, C.G. Lombana, J.S. Stumhofer, A. Laurence, E.H. Wilson, E. Huang, C.M. Tato, L.M. Johnson, V. Gafa, R. Lande, M.C. Gagliardi, M. Severa, E. Giacomini, M.E. Remoli, R. Nisini, M. Batten, J. Li, S. Yi, N.M. Kljavin, D.M. Danilenko, S. Lucas, J. Lee, F.J. de I.R. Humphreys, L. Edwards, G. Walzl, A.J. Rae, G. Dougan, S. Hill, T. Hussell, T. Zelante, A. De Luca, P. Bonifazi, C. Montagnoli, S. Bozza, S. Moretti, M.L. Belladonna, C. Vacca, C. Conte, P. Mosci, F. Bistoni, P. Puccetti, R.A. Kastelein, M. Kopf, L. Romani, IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance, Eur. J. Immunol. 37 (10) 3125–3134.

[13] C.J. Haines, J. Chen, W.M. Blumenstein, R. Jain, C. Chang, B. Joyce-Shaikh, K. Porth, K. Boniface, J. Mattson, B. Basham, S.M. Anderton, T.K. McNichlan, S. Sadekova, D.J. Cua, M.J. McCleughy, Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23, Cell Rep. 3 (5) (2013) 1378–1388.

[6] A. Villa, L. Ghiardi, J. Li, F.J. de Sauvage, IL-27 regulates IL-12 responsiveness of naive CD4+ T cells while IL-23, STAT3-dependent and -independent mechanisms, PNAS 102 (23) (2005) 15047–15052.

[14] S. Lucas, N. Ghiardi, J. Li, F.J. de Sauvage, IL-27 limits IL-12 responsiveness of naive CD4+ T cells while IL-23, STAT3-dependent and -independent mechanisms, PNAS 102 (23) (2005) 15047–15052.

[15] S. Lucas, N. Ghiardi, J. Li, F.J. de Sauvage, IL-27 limits IL-12 responsiveness of naive CD4+ T cells while IL-23, STAT3-dependent and -independent mechanisms, PNAS 102 (23) (2005) 15047–15052.

[16] A.O. Hall, D.P. Beiting, C. Tato, B. John, G. Oldenhove, C.G. Lombana, J.S. Stumhofer, A. Laurence, E.H. Wilson, E. Huang, C.M. Tato, L.M. Johnson, V. Gafa, R. Lande, M.C. Gagliardi, M. Severa, E. Giacomini, M.E. Remoli, R. Nisini, M. Batten, J. Li, S. Yi, N.M. Kljavin, D.M. Danilenko, S. Lucas, J. Lee, F.J. de I.R. Humphreys, L. Edwards, G. Walzl, A.J. Rae, G. Dougan, S. Hill, T. Hussell, T. Zelante, A. De Luca, P. Bonifazi, C. Montagnoli, S. Bozza, S. Moretti, M.L. Belladonna, C. Vacca, C. Conte, P. Mosci, F. Bistoni, P. Puccetti, R.A. Kastelein, M. Kopf, L. Romani, IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance, Eur. J. Immunol. 37 (10) 3125–3134.

[17] C.J. Haines, J. Chen, W.M. Blumenstein, R. Jain, C. Chang, B. Joyce-Shaikh, K. Porth, K. Boniface, J. Mattson, B. Basham, S.M. Anderton, T.K. McNichlan, S. Sadekova, D.J. Cua, M.J. McCleughy, Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23, Cell Rep. 3 (5) (2013) 1378–1388.

[18] A. Villa, L. Ghiardi, J. Li, F.J. de Sauvage, IL-27 regulates IL-12 responsiveness of naive CD4+ T cells while IL-23, STAT3-dependent and -independent mechanisms, PNAS 102 (23) (2005) 15047–15052.

[19] S. Lucas, N. Ghiardi, J. Li, F.J. de Sauvage, IL-27 limits IL-12 responsiveness of naive CD4+ T cells while IL-23, STAT3-dependent and -independent mechanisms, PNAS 102 (23) (2005) 15047–15052.

[20] S. Lucas, N. Ghiardi, J. Li, F.J. de Sauvage, IL-27 limits IL-12 responsiveness of naive CD4+ T cells while IL-23, STAT3-dependent and -independent mechanisms, PNAS 102 (23) (2005) 15047–15052.

[21] S. Lucas, N. Ghiardi, J. Li, F.J. de Sauvage, IL-27 limits IL-12 responsiveness of naive CD4+ T cells while IL-23, STAT3-dependent and -independent mechanisms, PNAS 102 (23) (2005) 15047–15052.
A. Thompson, S.J. Orr

Cytokine 111 (2018) 398-407

[47] J.L. Kreindler, C. Steele, N. Nguyen, Y.R. Chan, J.M. Pilewski, J.F. Alcorn, M.Y. Vas, S.J. Agla, P. Finelli, M. Blanchard, S.P. Zeigler, A. Logar, E. Hartigan, M. Kurs-Lasky, H. Rockette, A. Ray, J.K. Kolli, Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus by modifying T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J. Clin. Invest. 120 (9) (2010) 3242–3254.

B.J. Murdock, A.B. Shreiner, R.A. McDonald, J.J. Osterholzer, E.S. White, G.P. Chang, G.B. Ghandi, C. Corev, Comparison of IL-12p70, IL-12p40, and IL-18 in patients with repeated pulmonary exposure to Aspergillus fumigatus conidia. Infect. Immun. 79 (1) (2011) 125–135.

T.M. Bohl, H.L. Appelg, A. Rivera, L.A. Morgan, P.L. Chen, M. Feldmesser, E.G. Pamer, Aspergillus fumigatus triggers inflammatory responses by stage-spe-
cific beta-glucan display. PLoS pathogens 1 (3) (2005) e50.

G.M. Gurak, D.M. Underhill, L. Zhu, K.A. Marr, Dectin-1 and TLRs permit mac-
rophages to distinguish between different Aspergillus fumigatus cellular states. J. Immunol. 176 (6) (2006) 3717–3724.

M.G. Netea, A. Watt, J.W. Van der Meer, M.J. Fenton, T.J. Verver-Janssen, J.A. Gollob, E.A. Murphy, S. Mahajan, C.P. Schnipper, J. Ritz, D.A. Frank, Altered T cell responses in patients with allergic bronchopulmonary aspergillosis. Curr. Infect. Dis. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 40 (6) (2005) e55–e58.

W.E. Thierfelder, J.M. van Deun, K. Yamamoto, R.A. Tripp, S.R. Sarzaw, R.T. Carson, M.J. Sangster, D.A. Vignali, P.C. Doherty, G.C. Gruven, J.N. Ihle, Requirement for STAT3 in IL-12-mediated responses of natural killer cells and tissues. Nature 382 (6587) (1996) 171–174.

K. Shimoda, K. Kato, A. Aoki, T. Matsuda, A. Miyamoto, M. Shimamori, M. Yamashita, S. Kobayashi, Y. Asano, H. Gondo, K. Sekiguchi, K. Nakayama, T. Nakayama, T. Okamura, S. Okamura, Y. Niho, K. Nakayama, Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 13 (4) (2000) 561–571.

K. Shimoda, H. Tanaka, S. Tatsuki, K. Kato, M. Kato, K. Yamamoto, T. Yamamoto, H. Nukina, T. Hoshino, S. Asano, H. Gondo, T. Okamura, S. Okamura, K. Nakayama, K. Nakashima, Y. Niho, M. Harada, Partial impairment of IL-12p40 (IL-12) and IL-18 signaling in Tyk2-deficient mice, Blood 99 (2) (2002) 2094–2099.

B. Oppmann, R. Lesley, B. Blom, J.C. Timans, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Yano, K. Singh, F. Zonin, E. Vaisberg, T. Churakov, M. Liu, D. Gorman, J. Wagner, S. Zarzwsky, Y. Liu, J.S. Abrams, K.W. Moore, D. Rennick, R. De Waal-Malefyt, C. Hannum, J.F. Banaz, R.A. Kastelein, Novel p19 protein engages IL-
12p40 to form a cytokine, IL-23, with biological activities similar as well as dis-

C.A. Hunter, New IL-12-family members: IL-23 and IL-27, cytokines with di-

G. Trinchieri, S. Pless, C.A. Hunter, New IL-12-family members: IL-23 and IL-27, cytokines with di-

S. Gillessen, D. Carvajal, P. Ling, M.K. Gately, U. Gubler, A.S. Stern, P. Lin, K. Hollfelder, C. Su, Y.C. Pan, IL-12p40 homodimer: a potent IL-12 antagonist. Eur. J. Immunol. 25 (1) (1995) 200–206.

G. Trinchieri, S. Pless, R.A. Kastelein, The IL-12 family of heterodimeric cyto-

infection - inflammation and autoimmune disorders. Inflamm. Allergy Drug Targets 8 (3) (2009) 121–128.

C. Rangel-Castilla, L. Cordova, L. Penalva, P. de la Morena, M.R. Vinals, M. Vazquez, E. Opazo, C. Moya, C.M. Pena, J. Martinez-Argente, C.A. Hunter, C.G. Drake, P.J. Murray, D.A. Vignali, Interleukin-35 mediates induction of a potent suppressor cell population, Nat. Immunol. 11 (12) (2010) 1093–1098.

A. Caro, B. Mandar, D.B. Brandt, S. Bousset, C. de The, M. Modina, D. Moser, K. Ruzicka, M. Recher, Altered interleukin-12 responsiveness in TH1 and TH2 cells is associated with the differentiation of STAT5 and STAT1, Blood 91 (4) (1998) 1341–1354.

N. Ozbek, C. Fieschi, B.T. Yilmaz, I. De Beaucoudrey, B. Demirhan, J. Feinberg, Y.E. Bikzam, J.L. Casanova, Interleukin-12 receptor beta 1 chain deficiency in a child with chronic enteropathy and respiratory disease, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 40 (6) (2005) e55–e58.

A. Yamanaka, S. Hamano, Y. Miyazaki, I. Kinjyo, T. Ishibashi, A. Takeda, T.W. Mak, K. Himeno, A. Yoshimura, H. Yoshida, Two-sided roles of IL-27 in the induction of regulatory T cells and suppression of Th17 cells, Eur. J. Immunol. 40 (6) (2010) 1715–1725.

A. Yoshimura, T. Makino, J. Ohkawa, K. Kimata, T.W. Mak, K. Himeno, A. Yoshimura, H. Yoshida, Altered T cell responses in patients with chronic bronchial asthma. J. Immunol. 157 (5) (1996) 1951–1957.

O. Devergne, M. Hummel, H. Koeppen, M.M. Le Beau, E.C. Nathanson, E. Kieff, M. Birkenbach, A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J. Virol. 70 (2) (1996) 1143–1153.

S. Gillees, D. Carvajal, P.L. Fy, J.K. Podlsak, D.L. Stremo, P.C. Familietti, U. Gubler, A.S. Stern, M.S. Moser, M.K. Gately, IL-12p40 homodimer: a potent IL-12 antagonist. Eur. J. Immunol. 25 (1) (1995) 200–206.

F.J. Podlaski, V.B. Dandurand, D.J. Hulmes, Y.C. Pan, W. Venin, W. Danho, R. Chizzonite, M.K. Gatley, A.S. Stern, Molecular characterization of interleukin-12 A and B chains. Arch. Biochem. Biophys. 294 (1) (1992) 259–257.

P. Ling, M.K. Gatley, U. Gubler, A.S. Stern, A. Hof, K. Holffelder, C. Su, Y.C. Pan, J. Hakimi, Human IL-12 p40 homodimer binds to the IL-12 receptor but does not result in biological activity. J. Immunol. 157 (5) (1996) 1363–1367.

J.R. Picciotti, S.C. Yang, S.E. Chapman, J.L. Wykes, S.S. Watowich, C. Dong, STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282 (13) (2007) 9358–9363.

J. Arm, M. Gantzer, G.H. Fleischer, L. Frankel, Differential associations between the cytokine receptor genes and the susceptibility to albinism and to cutaneous leishmaniasis in the European population. J. Invest. Dermatol. 121 (4) (2003) 353–358.

A. Vignali, D.A. Veltri, H. Fio, C.S. Guy, K.M. Vignali, V. Chaturvedi, K.M. Vignali, T. Ishibashi, J. Bankoti, S. Mahajan, C.P. Schnipper, J. Ritz, D.A. Frank, Altered interleukin-12 responsiveness in TH1 and TH2 cells is associated with the...
A. Thompson, S.J. Orr

Cytokine 111 (2018) 398-407

A. Thompson, T. Zelante, C. D’Angelo, A. De Luca, S. Moretti, S. Bozza, K. Peruccio, R.G. Iannitti, G. Giovannini, C. Volpi, F. Fallarino, P. Puccetti, L. Romani, Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans, Microb. Immunol. 2 (4) (2009) 362-374.

[153] A. De Luca, C. Montagnoli, T. Zelante, P. Puccetti, S. Bozza, L. Romani, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[154] H. Yoshida, C.A. Hunter, The immunobiology of interleukin-27, Ann. Rev. Immunol. 33 (2015) 417-443.

[155] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity. Immunity 37 (6) (2012) 960-969.

[156] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[157] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.

[158] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[159] J. Flatot, M. Migaud, M. Tzouvelekis, J.P. Latge, H. Einsele, L. Romani, M.S. Topp, Distinct and complementary roles for the extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-function mutations in STAT1, J. Clin. Immunol. 36 (1) (2016) 73-84.

[160] K.G. Dixon, S.W. van der Kooij, D.A. Vignali, C. van Kooten, Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members, Eur. J. Immunol. 45 (6) (2015) 1736-1747.

[161] P. Bonifazi, T. Zelante, C. D’Angelo, A. De Luca, S. Moretti, S. Bozza, K. Perruccio, R.G. Iannitti, G. Giovannini, C. Volpi, F. Fallarino, P. Puccetti, L. Romani, Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans, Microb. Immunol. 2 (4) (2009) 362-374.

[162] A. De Luca, C. Montagnoli, T. Zelante, P. Puccetti, S. Bozza, L. Romani, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[163] H. Yoshida, C.A. Hunter, The immunobiology of interleukin-27, Ann. Rev. Immunol. 33 (2015) 417-443.

[164] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity. Immunity 37 (6) (2012) 960-969.

[165] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[166] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.

[167] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[168] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.

[169] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[170] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.

[171] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[172] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.

[173] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[174] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.

[175] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[176] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.

[177] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[178] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.

[179] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[180] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.

[181] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[182] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.

[183] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[184] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.

[185] T. Owaki, M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matsui, J. Mizuguchi, Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and TLR-dependent induction of type-I interferons. J. Immunol. 175 (3) (2005) 1873-1880.

[186] C.A. Hunter, R. Kastelein, Interleukin-27: balancing protective and pathological immunity, Immunity 37 (6) (2012) 960-969.